Thursday, September 22, 2011

Overwhelming

I was just informed by my UCLA study representative (we've moved into an extension study) that Otsuka will be using the Riverside Data to present to the FDA successful results in the Tolvaptan Trial. They are hoping for a fast track for the drug since it is currently in use for heart patients.
Wow.
Wow.